株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Integrated BioTherapeutics, Inc.の製品パイプライン分析

Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 251676
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
Integrated BioTherapeutics, Inc.の製品パイプライン分析 Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016
出版日: 2016年02月29日 ページ情報: 英文 34 Pages
概要

Integrated BioTherapeutics, Inc.は米国に本社をおくバイオテクノロジー企業です。新興の感染症治療用ワクチンや薬剤の創薬および開発を行っています。製品の他にも、in vitroおよびin vivoスクリーニング、動物モデルの開発、アッセイ開発、免疫原性試験、血清学試験の提供を行っています。

当レポートでは、Integrated BioTherapeutics, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Integrated BioTherapeutics, Inc. の基本情報

  • Integrated BioTherapeutics, Inc. の概要
  • 主要情報
  • 企業情報

Integrated BioTherapeutics, Inc. :R&Dの概要

  • 主な治療範囲

Integrated BioTherapeutics, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Integrated BioTherapeutics, Inc. :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Integrated BioTherapeutics, Inc. :薬剤プロファイル

  • STEBVax
  • AT-62-aa
  • Monoclonal Antibody 3 for Staphylococcus Aureus Infections
  • panfilovirus (multivalent) vaccine
  • SEB-HuMab
  • staphylococcal serogroup A (multivalent) vaccine
  • staphylococcus aureus (bivalent) vaccine
  • staphylococcus aureus (multivalent) vaccine
  • Monoclonal Antibodies for Ebola and Marburg Infections
  • Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV
  • Monoclonal Antibody 1 for Staphylococcus Aureus Infections
  • Monoclonal Antibody 2 for Staphylococcus Aureus Infections
  • Monoclonal Antibody 4 for Staphylococcus Aureus Infections

Integrated BioTherapeutics, Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Integrated BioTherapeutics, Inc. :最近のパイプライン情報

Integrated BioTherapeutics, Inc. :開発が休止されたプロジェクト

Integrated BioTherapeutics, Inc. :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07973CDB

Summary

Global Markets Direct's, 'Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Integrated BioTherapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Integrated BioTherapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Integrated BioTherapeutics, Inc.
  • The report provides overview of Integrated BioTherapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Integrated BioTherapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Integrated BioTherapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Integrated BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Integrated BioTherapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrated BioTherapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Integrated BioTherapeutics, Inc. Snapshot
    • Integrated BioTherapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Integrated BioTherapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Integrated BioTherapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Integrated BioTherapeutics, Inc. - Pipeline Products Glance
    • Integrated BioTherapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Integrated BioTherapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Integrated BioTherapeutics, Inc. - Drug Profiles
    • STEBVax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (Ebola + Marburg) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibodies for Ebola and Marburg Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-62aa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Ebola and Marburg Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Equine Encephalitis and Chikungunya
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 for Staphylococcus Aureus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Integrated BioTherapeutics, Inc. - Pipeline Analysis
    • Integrated BioTherapeutics, Inc. - Pipeline Products by Target
    • Integrated BioTherapeutics, Inc. - Pipeline Products by Route of Administration
    • Integrated BioTherapeutics, Inc. - Pipeline Products by Molecule Type
    • Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Integrated BioTherapeutics, Inc. - Recent Pipeline Updates
  • Integrated BioTherapeutics, Inc. - Dormant Projects
  • Integrated BioTherapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Integrated BioTherapeutics, Inc., Key Information
  • Integrated BioTherapeutics, Inc., Key Facts
  • Integrated BioTherapeutics, Inc. - Pipeline by Indication, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Integrated BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Integrated BioTherapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Integrated BioTherapeutics, Inc. - Phase I, 2016
  • Integrated BioTherapeutics, Inc. - Preclinical, 2016
  • Integrated BioTherapeutics, Inc. - Discovery, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Target, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Route of Administration, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Molecule Type, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Integrated BioTherapeutics, Inc. - Recent Pipeline Updates, 2016
  • Integrated BioTherapeutics, Inc. - Dormant Developmental Projects,2016

List of Figures

  • Integrated BioTherapeutics, Inc. - Pipeline by Indication, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Integrated BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Target, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Molecule Type, 2016
Back to Top